J. Kevin Buchi, President and Chief Executive Officer, Awarded the Pennsylvania Bio's Frank Baldino Bioscience CEO of the Yea...
13 March 2014 - 10:30PM
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today
announced that J. Kevin Buchi, President and Chief Executive
Officer, is the recipient of the 2014 Frank Baldino Jr. CEO of the
Year Award awarded by Pennsylvania Bio, the statewide life sciences
industry trade association. Mr. Buchi was honored at PA Bio's
Annual Dinner and Awards Celebration and Ceremony on March 12, 2014
in Philadelphia.
The Baldino Award recognizes a CEO who has shown visionary
leadership, exceptional achievement and unerring commitment to
patients and the industry.
"It is a true honor to be selected for this award. I'm
especially humbled given my 20 years history of closely working
with Frank," stated Mr. Buchi. "Frank always said that his success
was based upon the hard work of the people supporting him. That is
certainly true for me. We have assembled a terrific team at
TetraLogic and this award reflects their achievements."
About TetraLogic
TetraLogic is a clinical-stage biopharmaceutical company focused
on discovering and developing novel small molecule therapeutics
that mimic the Second Mitochondrial Activator of Caspases, or
SMAC-mimetics, and are designed to cause or enable abnormal cells
that are resistant to the body's immune system to self-destruct.
Birinapant, our clinical-stage product candidate, is
currently being tested in Phase 1 and Phase 2 clinical trials for
hematological malignancies and solid tumors.
CONTACT: Company Contact:
Pete A. Meyers
Chief Financial Officer and Treasurer
TetraLogic Pharmaceuticals Corporation
(610) 889-9900, x103
pete.meyers@tlog.com
Investor Relations Contact:
Ami Bavishi
Burns McClellan, Inc.
(212) 213-0006
abavishi@burnsmc.com
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jun 2024 to Jul 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about TetraLogic Pharmaceuticals Corporation (CE) (OTCMarkets): 0 recent articles
More News Articles